-
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
Groen, K., Smits, F., Nasserinejad, K., Levin, M.-D., Regelink, J. C., Timmers, G.-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Dec 2025, In: HemaSphere. 9, 12, e70268.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial
Smits, F., Groen, K., Levin, M.-D., Stege, C. A. M., van Kampen, R., van der Spek, E., Nijhof, I., Bilgin, Y. M., Thielen, N., Ludwig, I., de Waal, E. G. M., Sandberg, Y., Kentos, A., Timmers, G.-J., Regelink, J. C., Westerman, M., de Heer, K., Vekemans, M.-C., Durdu-Rayman, N. & HOVON 143 Study Group, 25 Nov 2025, In: Blood. 9, 22, p. 5828-5836 9 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
Seefat, M. R., Cucchi, D. G. J., van Boven, L., Durdu-Rayman, N., Groen, K., Levin, M. D., de Heer, K., de Valk, B., Wester, R., van der Spek, E., Rentenaar, R., Korst, C. L. B. M., Quik, M., O'Neill, C. A., Tzortzi, P., Smits, F., Mathot, R., Heerma van Voss, M. R., van de Donk, N. W. C. J. & Mutis, T. & 2 others, , 2025, (E-pub ahead of print) In: British Journal of Haematology.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications
